Clinical Trials

600 enrolled 14 charts 1 FDA

Ann Arbor Stage IIB Hodgkin Lymphoma

NCT03301220 2026-03-18

A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma

390 enrolled 12 charts 1 FDA

Smoldering Multiple Myeloma

NCT03375320 2026-03-18

Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors

298 enrolled 14 charts 1 FDA

EndocrineGastrointestinalNET

Non functioning pancreatic endocrine tumor, Adenoma, Islet Cell, Neuroendocrine Tumors

NCT05083169 2026-03-18

MajesTEC-3

587 enrolled 1 FDA

Multiple Myeloma

NCT03914612 2026-03-17

Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer

813 enrolled 16 charts 1 FDA

GynecologicSarcoma

Carcinosarcoma, Endometrial Neoplasms

NCT04404283 2026-03-17

ECHELON-3

238 enrolled 1 FDA

Lymphoma, Large B-Cell, Diffuse

NCT03748641 2026-03-16

MAGNITUDE

765 enrolled 16 charts 1 FDA

Prostatic Neoplasms, Castration-Resistant

NCT03164616 2026-03-13

POSEIDON

1,186 enrolled 26 charts 1 FDA

Non Small Cell Lung Cancer NSCLC

NCT03732677 2026-03-13

NIAGARA

1,063 enrolled 15 charts 1 FDA

Urinary Bladder Neoplasms

NCT03395197 2026-03-12

TALAPRO-2

1,054 enrolled 21 charts 1 FDA

mCRPC

NCT02655016 2026-03-10

A Study of Niraparib (GSK3985771) Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy

733 enrolled 21 charts 2 FDA

Gynecologic

Ovarian Neoplasms

NCT04971226 2026-03-10

A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP

406 enrolled 18 charts 1 FDA

MyeloidOther hematologic neoplasm

Philadelphia Chromosome, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT05091567 2026-03-10

IMforte

660 enrolled 23 charts 1 FDA

Small Cell Lung Carcinoma

NCT03336333 2026-03-09

SEQUOIA

590 enrolled 12 charts 1 FDA

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT05116189 2026-03-09

KEYNOTE-B96

643 enrolled 17 charts 1 FDA

Gynecologic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03036098 2026-03-06

CheckMate901

1,314 enrolled 23 charts 1 FDA

Urothelial Cancer

NCT02362594 2026-03-05

MK-3475-054

1,019 enrolled 16 charts 1 FDA

Dermatologic

Melanoma

NCT04494425 2026-03-04

DB-06

866 enrolled 25 charts 1 FDA

Breast Neoplasms

NCT03701334 2026-03-03

NATALEE

5,101 enrolled 2 FDA

Breast Neoplasms

NCT03521154 2026-02-27

LAURA

216 enrolled 25 charts 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT03875235 2026-02-27

TOPAZ-1

810 enrolled 24 charts 1 FDA

Biliary Tract Neoplasms

NCT04538664 2026-02-25

PAPILLON

308 enrolled 12 charts 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT02811861 2026-02-23

CLEAR

1,069 enrolled 12 charts 1 FDA

Carcinoma, Renal Cell

NCT04689828 2026-02-20

PSMAfore

469 enrolled 11 charts 1 FDA

Prostatic Neoplasms

NCT04039607 2026-02-19

CheckMate 9DW

732 enrolled 1 FDA

Carcinoma, Hepatocellular

NCT02972840 2026-02-18

A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL

635 enrolled 1 FDA

Lymphoma, Non-Hodgkin, Lymphoma, Mantle-Cell

NCT02032823 2026-02-17

OlympiA

1,836 enrolled 20 charts 1 FDA

Breast Neoplasms

NCT03504397 2026-02-13

Spotlight

565 enrolled 63 charts 1 FDA

Adenocarcinoma, Neoplasms, Stomach Neoplasms

NCT04497844 2026-02-13

AMPLITUDE

696 enrolled 15 charts 1 FDA

Metastatic Castration-sensitive Prostate Cancer

NCT03710603 2026-02-10

Perseus

709 enrolled 17 charts 1 FDA

Multiple Myeloma

NCT02970318 2026-02-06

A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL

310 enrolled 18 charts 1 FDA

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03274492 2026-02-06

POLARIX

1,000 enrolled 1 FDA

Lymphoma, Large B-Cell, Diffuse

NCT03653507 2026-02-06

GLOW

507 enrolled 65 charts 1 FDA

Adenocarcinoma, Neoplasms, Stomach Neoplasms

NCT05198934 2026-02-06

CodeBreak300

160 enrolled 1 FDA

Colorectal Neoplasms

NCT04656652 2026-02-05

Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01)

605 enrolled 14 charts 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT04988295 2026-02-05

MARIPOSA-2

776 enrolled 13 charts 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT04487080 2026-02-04

MARIPOSA

1,074 enrolled 13 charts 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT05104866 2026-02-04

A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)

732 enrolled 22 charts 1 FDA

Breast Neoplasms, Neoplasm Metastasis

NCT02246621 2026-02-03

MONARCH 3

493 enrolled 23 charts 1 FDA

Breast Neoplasms

NCT01946204 2026-02-02

SPARTAN

1,207 enrolled 15 charts 1 FDA

Prostatic Neoplasms

NCT02489318 2026-02-02

TITAN

1,052 enrolled 13 charts 1 FDA

Prostatic Neoplasms

NCT03390504 2026-02-02

THOR

629 enrolled 32 charts 1 FDA

Urothelial Cancer

NCT03652064 2026-01-20

A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy

395 enrolled 1 FDA

Multiple Myeloma

NCT02411448 2026-01-16

RELAY

545 enrolled 24 charts 2 FDA

Carcinoma, Non-Small-Cell Lung

NCT03298451 2026-01-14

HIMALAYA

1,324 enrolled 31 charts 1 FDA

Carcinoma, Hepatocellular

NCT04924608 2026-01-12

KOMET

145 enrolled 17 charts 1 FDA

CNS

Neurofibromatosis 1, Neurofibroma, Plexiform

NCT02511106 2026-01-05

ADAURA

682 enrolled 20 charts 2 FDA

Stage IB-IIIA Non-small Cell Lung Carcinoma

NCT05740566 2026-01-05

DeLLphi-304

509 enrolled 11 charts 1 FDA

Small Cell Lung Carcinoma

NCT04269200 2025-12-23

DUO-E

805 enrolled 18 charts 1 FDA

Gynecologic

Endometrial Neoplasms

NCT04680052 2025-12-22

InMIND

654 enrolled 40 charts 1 FDA